UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer

Journal of allergy and clinical immunology, 2016-05, Vol.137 (5), p.1610-1613.e7

2016

Volltextzugriff (PDF)

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer

Journal of allergy and clinical immunology, 2016-12, Vol.138 (6), p.1712-1715

2016

Volltextzugriff (PDF)

Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction

The New England journal of medicine, 2004-09, Vol.351 (13), p.1285-1295

2004

Volltextzugriff (PDF)

Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial

The Lancet (British edition), 2016-01, Vol.387 (10016), p.349-356

2016

Volltextzugriff (PDF)

Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both

Circulation (New York, N.Y.), 2010-08, Vol.122 (6), p.597-602

2010

Volltextzugriff (PDF)

Femoral Vascular Closure Devices and Bleeding, Hemostasis, and Ambulation Following Percutaneous Coronary Intervention

Journal of the American Heart Association, 2023-01, Vol.12 (1), p.e025666-e025666

2023

Volltextzugriff (PDF)

A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial

European heart journal, 2013-08, Vol.34 (31), p.2481-2489

2013

Volltextzugriff (PDF)

Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial

The American heart journal, 2020-05, Vol.223, p.84-86

2020

Volltextzugriff (PDF)

SUBCUTANEOUS FIXA INHIBITOR PROVIDES PROLONGED ANTICOAGULATION: THE FIRST SUCCESSFUL SUBCUTANEOUS APPLICATION OF AN APTAMER

Journal of the American College of Cardiology, 2010-03, Vol.55 (10), p.A172.E1618-A172.E1618

2010

Volltextzugriff (PDF)

Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism

Arteriosclerosis, thrombosis, and vascular biology, 2010-03, Vol.30 (3), p.382-387

2010

Volltextzugriff (PDF)

Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes

European heart journal. Acute cardiovascular care, 2019-09, Vol.8 (6), p.520-526

2019

Volltextzugriff (PDF)

First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention

Circulation (New York, N.Y.), 2010-08, Vol.122 (6), p.614-622

2010

Volltextzugriff (PDF)

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial

The American heart journal, 2011-02, Vol.161 (2), p.261-268.e2

2011

Volltextzugriff (PDF)

Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy

European heart journal, 2011-10, Vol.32 (19), p.2412-2419

2011

Volltextzugriff (PDF)

Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction

European journal of heart failure, 2006-10, Vol.8 (6), p.591-598

2006

Volltextzugriff (PDF)

FEMORAL VASCULAR CLOSURE DEVICES AND BLEEDING, HEMOSTASIS, AND AMBULATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION

Journal of the American College of Cardiology, 2022-03, Vol.79 (9), p.831

2022

Volltextzugriff (PDF)

Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study

EuroIntervention, 2014-08, Vol.10 (4), p.431-438

2014

Volltextzugriff (PDF)

Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction

Hypertension (Dallas, Tex. 1979), 2008-01, Vol.51 (1), p.48-54

2008

Volltextzugriff (PDF)

Feasibility of at-home motor assessments using wireless technology in patients with myelopathy: year 1 follow up of CYGNET, an observational study of patients with adrenomyeloneuropathy (P6-6.006)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery

BMC cardiovascular disorders, 2010-02, Vol.10 (1), p.7-7, Article 7

2010

Volltextzugriff (PDF)

Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trial

The Journal of invasive cardiology, 2013-11, Vol.25 (11), p.593-599

2013

Volltextzugriff (PDF)

Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-07, Vol.24 (4), p.e167-e172

2018

Volltextzugriff (PDF)

Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both

The New England journal of medicine, 2003-11, Vol.349 (20), p.1893-1906

2003

Volltextzugriff (PDF)

The 1st WFH Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world

Haemophilia : the official journal of the World Federation of Hemophilia, 2019-03, Vol.25 (2), p.189-194

2019

Volltextzugriff (PDF)

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus

Journal of hypertension, 2007-09, Vol.25 (9), p.1921-1926

2007

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(45)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Humans
(25)
Cardiovascular System & Cardiology
(24)
Female
(22)
Male
(20)
Middle Aged
(20)
Cardiac & Cardiovascular Systems
(19)
Aged
(18)
Biological And Medical Sciences
(13)
Medical Sciences
(13)
Cardiology. Vascular System
(10)
Peripheral Vascular Disease
(9)
Treatment Outcome
(9)
Valsartan
(9)
Anticoagulants - Therapeutic Use
(8)
Acute Coronary Syndromes
(7)
Aptamers, Nucleotide - Therapeutic Use
(7)
Factor Ixa - Antagonists & Inhibitors
(7)
Heart
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer

Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction

Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial

Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both

Femoral Vascular Closure Devices and Bleeding, Hemostasis, and Ambulation Following Percutaneous Coronary Intervention

A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial

Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial

SUBCUTANEOUS FIXA INHIBITOR PROVIDES PROLONGED ANTICOAGULATION: THE FIRST SUCCESSFUL SUBCUTANEOUS APPLICATION OF AN APTAMER

Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism

Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes

First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial

Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy

Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction

FEMORAL VASCULAR CLOSURE DEVICES AND BLEEDING, HEMOSTASIS, AND AMBULATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION

Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study

Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction

Feasibility of at-home motor assessments using wireless technology in patients with myelopathy: year 1 follow up of CYGNET, an observational study of patients with adrenomyeloneuropathy (P6-6.006)

Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery

Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trial

Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project

Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both

The 1st WFH Gene Therapy Round Table: Understanding the landscape and challenges of gene therapy for haemophilia around the world

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus

Aktive Filter

Suchergebnisse filtern